_id
691859aa3c536f8df2317b75
Ticker
0MGB.LSE
Name
Genmab
Exchange
LSE
Address
Carl Jacobsens Vej 30, Copenhagen, Denmark, 2500
Country
UK
Sector
Industry
Currency
DKK
Website
https://www.genmab.com
Description
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Last Close
2125.5
Volume
5390
Current Price
2121.3999
Change
5.3999
Last Updated
2026-01-08T14:28:17.752Z
Image
https://logo.clearbit.com/www.genmab.com
Ipo Date
-
Market Cap
147932300000
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2023-06-30
Revenue
-
Cost Of Revenue
-
Gross Profit
-
Operating Expenses
-
Operating Income
-
Interest Expense
-
Pretax Income
-
Net Income
-
Eps
-
Dividends Per Share
-
Shares Outstanding
0
Income Tax Expense
366000000
EBITDA
-
Operating Margin
-
Total Other Income Expense Net
-
Cash
-
Short Term Investments
-
Receivables
4814000000
Inventories
51000000
Total Current Assets
29749000000
Property Plant Equipment
1634000000
Total Assets
-
Payables
-
Short Term Debt
-
Long Term Debt
-
Total Liabilities
1993000000
Equity
-
Bs_currency_symbol
DKK
Depreciation
23000000
Change In Working Capital
-
Cash From Operations
436000000
Capital Expenditures
97000000
Cash From Investing
-1835000000
Cash From Financing
7000000
Net Change In Cash
-1414000000
Cf_currency_symbol
DKK
PE
-
PB
-
ROE
-
ROA
-
FCF
339000000
Fcf Percent
-
Piotroski FScore
1
Health Score
46
Deep Value Investing Score
0.5
Defensive Investing Score
3
Dividend Investing Score
1.5
Economic Moat Investing Score
1.5
Garp Investing Score
0
Growth Investing Score
0
Momentum Investing Score
2.5
Net Net Investing Score
0
Quality Investing Score
0.5
Value Investing Score
0.5
Quarters > 0 > quarter
2023-06-30
Quarters > 0 > income Statement > revenue
-
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
-
Quarters > 0 > income Statement > operating Expenses
-
Quarters > 0 > income Statement > operating Income
-
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-
Quarters > 0 > income Statement > net Income
-
Quarters > 0 > income Statement > eps
-
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
-
Quarters > 0 > income Statement > income Tax Expense
366000000
Quarters > 0 > income Statement > EBITDA
-
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
-
Quarters > 0 > income Statement > currency_symbol
DKK
Quarters > 0 > balance Sheet > cash
-
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
4814000000
Quarters > 0 > balance Sheet > inventories
51000000
Quarters > 0 > balance Sheet > total Current Assets
29749000000
Quarters > 0 > balance Sheet > property Plant Equipment
1634000000
Quarters > 0 > balance Sheet > total Assets
-
Quarters > 0 > balance Sheet > payables
-
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
1993000000
Quarters > 0 > balance Sheet > equity
-
Quarters > 0 > balance Sheet > currency_symbol
DKK
Quarters > 0 > cash Flow > net Income
1357000000
Quarters > 0 > cash Flow > depreciation
23000000
Quarters > 0 > cash Flow > change In Working Capital
-
Quarters > 0 > cash Flow > cash From Operations
436000000
Quarters > 0 > cash Flow > capital Expenditures
97000000
Quarters > 0 > cash Flow > cash From Investing
-1835000000
Quarters > 0 > cash Flow > cash From Financing
7000000
Quarters > 0 > cash Flow > net Change In Cash
-1414000000
Quarters > 0 > cash Flow > currency_symbol
DKK
Quarters > 0 > ratios > PE
-
Quarters > 0 > ratios > PB
-
Quarters > 0 > ratios > ROE
-
Quarters > 0 > ratios > ROA
-
Quarters > 0 > ratios > FCF
339000000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
46
Quarters > 1 > quarter
2023-03-31
Quarters > 1 > income Statement > revenue
-
Quarters > 1 > income Statement > cost Of Revenue
-
Quarters > 1 > income Statement > gross Profit
-
Quarters > 1 > income Statement > operating Expenses
-
Quarters > 1 > income Statement > operating Income
-
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-
Quarters > 1 > income Statement > net Income
-
Quarters > 1 > income Statement > eps
-
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
-
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
-
Quarters > 1 > income Statement > currency_symbol
DKK
Quarters > 1 > balance Sheet > cash
-
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
-
Quarters > 1 > balance Sheet > property Plant Equipment
-
Quarters > 1 > balance Sheet > total Assets
-
Quarters > 1 > balance Sheet > payables
-
Quarters > 1 > balance Sheet > short Term Debt
-
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
-
Quarters > 1 > balance Sheet > equity
-
Quarters > 1 > balance Sheet > currency_symbol
-
Quarters > 1 > cash Flow > net Income
226000000
Quarters > 1 > cash Flow > depreciation
23000000
Quarters > 1 > cash Flow > change In Working Capital
-
Quarters > 1 > cash Flow > cash From Operations
436000000
Quarters > 1 > cash Flow > capital Expenditures
97000000
Quarters > 1 > cash Flow > cash From Investing
-1835000000
Quarters > 1 > cash Flow > cash From Financing
7000000
Quarters > 1 > cash Flow > net Change In Cash
-1414000000
Quarters > 1 > cash Flow > currency_symbol
DKK
Quarters > 1 > ratios > PE
-
Quarters > 1 > ratios > PB
-
Quarters > 1 > ratios > ROE
-
Quarters > 1 > ratios > ROA
-
Quarters > 1 > ratios > FCF
339000000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
46
Quarters > 2 > quarter
2022-12-31
Quarters > 2 > income Statement > revenue
-
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
-
Quarters > 2 > income Statement > operating Expenses
-
Quarters > 2 > income Statement > operating Income
-
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-
Quarters > 2 > income Statement > net Income
-
Quarters > 2 > income Statement > eps
-
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
-
Quarters > 2 > income Statement > income Tax Expense
78000000
Quarters > 2 > income Statement > EBITDA
-
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
-
Quarters > 2 > income Statement > currency_symbol
DKK
Quarters > 2 > balance Sheet > cash
-
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
6053000000
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
28377000000
Quarters > 2 > balance Sheet > property Plant Equipment
1322000000
Quarters > 2 > balance Sheet > total Assets
-
Quarters > 2 > balance Sheet > payables
-
Quarters > 2 > balance Sheet > short Term Debt
-
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
1823000000
Quarters > 2 > balance Sheet > equity
-
Quarters > 2 > balance Sheet > currency_symbol
DKK
Quarters > 2 > cash Flow > net Income
584000000
Quarters > 2 > cash Flow > depreciation
345000000
Quarters > 2 > cash Flow > change In Working Capital
-
Quarters > 2 > cash Flow > cash From Operations
398000000
Quarters > 2 > cash Flow > capital Expenditures
110000000
Quarters > 2 > cash Flow > cash From Investing
-136000000
Quarters > 2 > cash Flow > cash From Financing
131000000
Quarters > 2 > cash Flow > net Change In Cash
-484000000
Quarters > 2 > cash Flow > currency_symbol
DKK
Quarters > 2 > ratios > PE
-
Quarters > 2 > ratios > PB
-
Quarters > 2 > ratios > ROE
-
Quarters > 2 > ratios > ROA
-
Quarters > 2 > ratios > FCF
288000000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
46
Quarters > 3 > quarter
2022-09-30
Quarters > 3 > income Statement > revenue
-
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
-
Quarters > 3 > income Statement > operating Expenses
-
Quarters > 3 > income Statement > operating Income
-
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-
Quarters > 3 > income Statement > net Income
-
Quarters > 3 > income Statement > eps
-
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
-
Quarters > 3 > income Statement > income Tax Expense
690000000
Quarters > 3 > income Statement > EBITDA
-
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
-
Quarters > 3 > income Statement > currency_symbol
DKK
Quarters > 3 > balance Sheet > cash
-
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
4951000000
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
28739000000
Quarters > 3 > balance Sheet > property Plant Equipment
1289000000
Quarters > 3 > balance Sheet > total Assets
-
Quarters > 3 > balance Sheet > payables
-
Quarters > 3 > balance Sheet > short Term Debt
-
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
2988000000
Quarters > 3 > balance Sheet > equity
-
Quarters > 3 > balance Sheet > currency_symbol
DKK
Quarters > 3 > cash Flow > net Income
2582000000
Quarters > 3 > cash Flow > depreciation
22000000
Quarters > 3 > cash Flow > change In Working Capital
-
Quarters > 3 > cash Flow > cash From Operations
1968000000
Quarters > 3 > cash Flow > capital Expenditures
82000000
Quarters > 3 > cash Flow > cash From Investing
-1382000000
Quarters > 3 > cash Flow > cash From Financing
-642000000
Quarters > 3 > cash Flow > net Change In Cash
561000000
Quarters > 3 > cash Flow > currency_symbol
DKK
Quarters > 3 > ratios > PE
-
Quarters > 3 > ratios > PB
-
Quarters > 3 > ratios > ROE
-
Quarters > 3 > ratios > ROA
-
Quarters > 3 > ratios > FCF
1886000000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
46
Annuals > 0 > quarter
2022-12-31
Annuals > 0 > income Statement > revenue
-
Annuals > 0 > income Statement > cost Of Revenue
-
Annuals > 0 > income Statement > gross Profit
-
Annuals > 0 > income Statement > operating Expenses
-
Annuals > 0 > income Statement > operating Income
-
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
-
Annuals > 0 > income Statement > net Income
-
Annuals > 0 > income Statement > eps
-
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
-
Annuals > 0 > income Statement > income Tax Expense
1513000000
Annuals > 0 > income Statement > EBITDA
-
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
-
Annuals > 0 > income Statement > currency_symbol
DKK
Annuals > 0 > balance Sheet > cash
-
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
6053000000
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
28377000000
Annuals > 0 > balance Sheet > property Plant Equipment
1322000000
Annuals > 0 > balance Sheet > total Assets
-
Annuals > 0 > balance Sheet > payables
-
Annuals > 0 > balance Sheet > short Term Debt
-
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
1823000000
Annuals > 0 > balance Sheet > equity
-
Annuals > 0 > balance Sheet > currency_symbol
DKK
Annuals > 0 > cash Flow > net Income
5522000000
Annuals > 0 > cash Flow > depreciation
398000000
Annuals > 0 > cash Flow > change In Working Capital
-
Annuals > 0 > cash Flow > cash From Operations
3912000000
Annuals > 0 > cash Flow > capital Expenditures
317000000
Annuals > 0 > cash Flow > cash From Investing
-2761000000
Annuals > 0 > cash Flow > cash From Financing
-789000000
Annuals > 0 > cash Flow > net Change In Cash
936000000
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-
Annuals > 0 > ratios > PB
-
Annuals > 0 > ratios > ROE
-
Annuals > 0 > ratios > ROA
-
Annuals > 0 > ratios > FCF
3595000000
Annuals > 0 > ratios > Piotroski FScore
1
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
46
Annuals > 1 > quarter
2021-12-31
Annuals > 1 > income Statement > revenue
-
Annuals > 1 > income Statement > cost Of Revenue
-
Annuals > 1 > income Statement > gross Profit
-
Annuals > 1 > income Statement > operating Expenses
-
Annuals > 1 > income Statement > operating Income
-
Annuals > 1 > income Statement > interest Expense
0
Annuals > 1 > income Statement > pretax Income
-
Annuals > 1 > income Statement > net Income
-
Annuals > 1 > income Statement > eps
-
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
-
Annuals > 1 > income Statement > income Tax Expense
975000000
Annuals > 1 > income Statement > EBITDA
-
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
-
Annuals > 1 > income Statement > currency_symbol
DKK
Annuals > 1 > balance Sheet > cash
-
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
3398000000
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
22736000000
Annuals > 1 > balance Sheet > property Plant Equipment
975000000
Annuals > 1 > balance Sheet > total Assets
-
Annuals > 1 > balance Sheet > payables
350000000
Annuals > 1 > balance Sheet > short Term Debt
-
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
1568000000
Annuals > 1 > balance Sheet > equity
-
Annuals > 1 > balance Sheet > currency_symbol
DKK
Annuals > 1 > cash Flow > net Income
3008000000
Annuals > 1 > cash Flow > depreciation
304000000
Annuals > 1 > cash Flow > change In Working Capital
-
Annuals > 1 > cash Flow > cash From Operations
2228000000
Annuals > 1 > cash Flow > capital Expenditures
252000000
Annuals > 1 > cash Flow > cash From Investing
-961000000
Annuals > 1 > cash Flow > cash From Financing
-420000000
Annuals > 1 > cash Flow > net Change In Cash
1697000000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-
Annuals > 1 > ratios > PB
-
Annuals > 1 > ratios > ROE
-
Annuals > 1 > ratios > ROA
-
Annuals > 1 > ratios > FCF
1976000000
Annuals > 1 > ratios > Piotroski FScore
1
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
46
Annuals > 2 > quarter
2020-12-31
Annuals > 2 > income Statement > revenue
10111000000
Annuals > 2 > income Statement > cost Of Revenue
-
Annuals > 2 > income Statement > gross Profit
-
Annuals > 2 > income Statement > operating Expenses
-
Annuals > 2 > income Statement > operating Income
6313000000
Annuals > 2 > income Statement > interest Expense
0
Annuals > 2 > income Statement > pretax Income
5904000000
Annuals > 2 > income Statement > net Income
4758000000
Annuals > 2 > income Statement > eps
-
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
-
Annuals > 2 > income Statement > income Tax Expense
1146000000
Annuals > 2 > income Statement > EBITDA
-
Annuals > 2 > income Statement > operating Margin
62.43694985659183
Annuals > 2 > income Statement > total Other Income Expense Net
-
Annuals > 2 > income Statement > currency_symbol
DKK
Annuals > 2 > balance Sheet > cash
7260000000
Annuals > 2 > balance Sheet > short Term Investments
8819000000
Annuals > 2 > balance Sheet > receivables
2712000000
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
18791000000
Annuals > 2 > balance Sheet > property Plant Equipment
736000000
Annuals > 2 > balance Sheet > total Assets
21143000000
Annuals > 2 > balance Sheet > payables
-
Annuals > 2 > balance Sheet > short Term Debt
-
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
2022000000
Annuals > 2 > balance Sheet > equity
19121000000
Annuals > 2 > balance Sheet > currency_symbol
DKK
Annuals > 2 > cash Flow > net Income
4758000000
Annuals > 2 > cash Flow > depreciation
266000000
Annuals > 2 > cash Flow > change In Working Capital
-339000000
Annuals > 2 > cash Flow > cash From Operations
6433000000
Annuals > 2 > cash Flow > capital Expenditures
307000000
Annuals > 2 > cash Flow > cash From Investing
-2351000000
Annuals > 2 > cash Flow > cash From Financing
71000000
Annuals > 2 > cash Flow > net Change In Cash
3708000000
Annuals > 2 > cash Flow > currency_symbol
DKK
Annuals > 2 > ratios > PE
-
Annuals > 2 > ratios > PB
-
Annuals > 2 > ratios > ROE
24.883635793107057
Annuals > 2 > ratios > ROA
22.50390200066216
Annuals > 2 > ratios > FCF
6126000000
Annuals > 2 > ratios > Piotroski FScore
4
Annuals > 2 > ratios > fcf Percent
0.6058747898328553
Annuals > 2 > health Score
82
Annuals > 3 > quarter
2019-12-31
Annuals > 3 > income Statement > revenue
5366000000
Annuals > 3 > income Statement > cost Of Revenue
-
Annuals > 3 > income Statement > gross Profit
-
Annuals > 3 > income Statement > operating Expenses
-
Annuals > 3 > income Statement > operating Income
2638000000
Annuals > 3 > income Statement > interest Expense
0
Annuals > 3 > income Statement > pretax Income
2859000000
Annuals > 3 > income Statement > net Income
2166000000
Annuals > 3 > income Statement > eps
-
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
-
Annuals > 3 > income Statement > income Tax Expense
693000000
Annuals > 3 > income Statement > EBITDA
-
Annuals > 3 > income Statement > operating Margin
49.1613865076407
Annuals > 3 > income Statement > total Other Income Expense Net
-
Annuals > 3 > income Statement > currency_symbol
DKK
Annuals > 3 > balance Sheet > cash
3552000000
Annuals > 3 > balance Sheet > short Term Investments
7419000000
Annuals > 3 > balance Sheet > receivables
2990000000
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
13961000000
Annuals > 3 > balance Sheet > property Plant Equipment
414000000
Annuals > 3 > balance Sheet > total Assets
15144000000
Annuals > 3 > balance Sheet > payables
-
Annuals > 3 > balance Sheet > short Term Debt
-
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
1096000000
Annuals > 3 > balance Sheet > equity
14048000000
Annuals > 3 > balance Sheet > currency_symbol
DKK
Annuals > 3 > cash Flow > net Income
2166000000
Annuals > 3 > cash Flow > depreciation
167000000
Annuals > 3 > cash Flow > change In Working Capital
-1603000000
Annuals > 3 > cash Flow > cash From Operations
1326000000
Annuals > 3 > cash Flow > capital Expenditures
79000000
Annuals > 3 > cash Flow > cash From Investing
-1983000000
Annuals > 3 > cash Flow > cash From Financing
3660000000
Annuals > 3 > cash Flow > net Change In Cash
3019000000
Annuals > 3 > cash Flow > currency_symbol
DKK
Annuals > 3 > ratios > PE
-
Annuals > 3 > ratios > PB
-
Annuals > 3 > ratios > ROE
15.418564920273347
Annuals > 3 > ratios > ROA
14.3026941362916
Annuals > 3 > ratios > FCF
1247000000
Annuals > 3 > ratios > Piotroski FScore
3
Annuals > 3 > ratios > fcf Percent
0.23238911666045473
Annuals > 3 > health Score
77
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > final Score
50
Profitability > verdict
Weak
Risk > final Score
50
Risk > verdict
High
Liquidity > final Score
50
Liquidity > verdict
Weak
Prev Valuations > 0
50
Prev Valuations > 1
50
Prev Valuations > 2
50
Prev Profitabilities > 0
50
Prev Profitabilities > 1
50
Prev Profitabilities > 2
50
Prev Risks > 0
50
Prev Risks > 1
50
Prev Risks > 2
50
Prev Liquidities > 0
50
Prev Liquidities > 1
50
Prev Liquidities > 2
50
Updated At
2026-01-22T21:19:47.841Z
Earnings History > 0 > period
2026-03-31
Earnings History > 0 > report Date
2026-05-06
Earnings History > 0 > date
2026-03-31
Earnings History > 0 > before After Market
AfterMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-12-31
Earnings History > 1 > report Date
2026-02-05
Earnings History > 1 > date
2025-12-31
Earnings History > 1 > before After Market
AfterMarket
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-
Earnings History > 1 > eps Estimate
27.64
Earnings History > 1 > eps Difference
0
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2025-09-30
Earnings History > 2 > report Date
2025-11-06
Earnings History > 2 > date
2025-09-30
Earnings History > 2 > before After Market
AfterMarket
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
41.2601
Earnings History > 2 > eps Estimate
31.81
Earnings History > 2 > eps Difference
9.4501
Earnings History > 2 > surprise Percent
29.708
Earnings History > 3 > period
2025-06-30
Earnings History > 3 > report Date
2025-08-07
Earnings History > 3 > date
2025-06-30
Earnings History > 3 > before After Market
AfterMarket
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
35.9368
Earnings History > 3 > eps Estimate
25.72
Earnings History > 3 > eps Difference
10.2168
Earnings History > 3 > surprise Percent
39.7232
Earnings History > 4 > period
2025-03-31
Earnings History > 4 > report Date
2025-05-08
Earnings History > 4 > date
2025-03-31
Earnings History > 4 > before After Market
AfterMarket
Earnings History > 4 > currency
DKK
Earnings History > 4 > eps Actual
21.6185
Earnings History > 4 > eps Estimate
15.26
Earnings History > 4 > eps Difference
6.3585
Earnings History > 4 > surprise Percent
41.6678
Earnings History > 5 > period
2024-12-31
Earnings History > 5 > report Date
2025-02-12
Earnings History > 5 > date
2024-12-31
Earnings History > 5 > before After Market
AfterMarket
Earnings History > 5 > currency
DKK
Earnings History > 5 > eps Actual
60.12
Earnings History > 5 > eps Estimate
24.9
Earnings History > 5 > eps Difference
35.22
Earnings History > 5 > surprise Percent
141.4458
Earnings History > 6 > period
2024-09-30
Earnings History > 6 > report Date
2024-11-06
Earnings History > 6 > date
2024-09-30
Earnings History > 6 > before After Market
AfterMarket
Earnings History > 6 > currency
DKK
Earnings History > 6 > eps Actual
19.81
Earnings History > 6 > eps Estimate
20.99
Earnings History > 6 > eps Difference
-1.18
Earnings History > 6 > surprise Percent
-5.6217
Earnings History > 7 > period
2024-06-30
Earnings History > 7 > report Date
2024-08-08
Earnings History > 7 > date
2024-06-30
Earnings History > 7 > before After Market
AfterMarket
Earnings History > 7 > currency
DKK
Earnings History > 7 > eps Actual
21.7
Earnings History > 7 > eps Estimate
21.35
Earnings History > 7 > eps Difference
0.35
Earnings History > 7 > surprise Percent
1.6393
Earnings History > 8 > period
2024-03-31
Earnings History > 8 > report Date
2024-05-02
Earnings History > 8 > date
2024-03-31
Earnings History > 8 > before After Market
AfterMarket
Earnings History > 8 > currency
DKK
Earnings History > 8 > eps Actual
20.18
Earnings History > 8 > eps Estimate
13.93
Earnings History > 8 > eps Difference
6.25
Earnings History > 8 > surprise Percent
44.8672
Earnings History > 9 > period
2023-12-31
Earnings History > 9 > report Date
2024-03-13
Earnings History > 9 > date
2023-12-31
Earnings History > 9 > before After Market
AfterMarket
Earnings History > 9 > currency
DKK
Earnings History > 9 > eps Actual
9.66
Earnings History > 9 > eps Estimate
21.52
Earnings History > 9 > eps Difference
-11.86
Earnings History > 9 > surprise Percent
-55.1115
Earnings History > 10 > period
2023-09-30
Earnings History > 10 > report Date
2023-11-07
Earnings History > 10 > date
2023-09-30
Earnings History > 10 > before After Market
-
Earnings History > 10 > currency
DKK
Earnings History > 10 > eps Actual
32.46
Earnings History > 10 > eps Estimate
32.32
Earnings History > 10 > eps Difference
0.14
Earnings History > 10 > surprise Percent
0.4332
Earnings History > 11 > period
2023-06-30
Earnings History > 11 > report Date
2023-08-03
Earnings History > 11 > date
2023-06-30
Earnings History > 11 > before After Market
-
Earnings History > 11 > currency
DKK
Earnings History > 11 > eps Actual
20.61
Earnings History > 11 > eps Estimate
20.61
Earnings History > 11 > eps Difference
0
Earnings History > 11 > surprise Percent
0
Earnings History > 12 > period
2023-03-31
Earnings History > 12 > report Date
2023-05-10
Earnings History > 12 > date
2023-03-31
Earnings History > 12 > before After Market
-
Earnings History > 12 > currency
DKK
Earnings History > 12 > eps Actual
3.43
Earnings History > 12 > eps Estimate
3.43
Earnings History > 12 > eps Difference
0
Earnings History > 12 > surprise Percent
0
Earnings History > 13 > period
2022-12-31
Earnings History > 13 > report Date
2023-02-22
Earnings History > 13 > date
2022-12-31
Earnings History > 13 > before After Market
-
Earnings History > 13 > currency
DKK
Earnings History > 13 > eps Actual
8.77
Earnings History > 13 > eps Estimate
8.77
Earnings History > 13 > eps Difference
0
Earnings History > 13 > surprise Percent
0
Earnings History > 14 > period
2022-09-30
Earnings History > 14 > report Date
2022-11-09
Earnings History > 14 > date
2022-09-30
Earnings History > 14 > before After Market
-
Earnings History > 14 > currency
DKK
Earnings History > 14 > eps Actual
39.17
Earnings History > 14 > eps Estimate
39.17
Earnings History > 14 > eps Difference
0
Earnings History > 14 > surprise Percent
0
Earnings History > 15 > period
2022-06-30
Earnings History > 15 > report Date
2022-08-10
Earnings History > 15 > date
2022-06-30
Earnings History > 15 > before After Market
-
Earnings History > 15 > currency
DKK
Earnings History > 15 > eps Actual
28.66
Earnings History > 15 > eps Estimate
28.66
Earnings History > 15 > eps Difference
0
Earnings History > 15 > surprise Percent
0
Earnings History > 16 > period
2022-03-31
Earnings History > 16 > report Date
2022-05-11
Earnings History > 16 > date
2022-03-31
Earnings History > 16 > before After Market
-
Earnings History > 16 > currency
DKK
Earnings History > 16 > eps Actual
7.05
Earnings History > 16 > eps Estimate
7.05
Earnings History > 16 > eps Difference
0
Earnings History > 16 > surprise Percent
0
Earnings History > 17 > period
2021-12-31
Earnings History > 17 > report Date
2022-02-16
Earnings History > 17 > date
2021-12-31
Earnings History > 17 > before After Market
-
Earnings History > 17 > currency
DKK
Earnings History > 17 > eps Actual
10.82
Earnings History > 17 > eps Estimate
10.82
Earnings History > 17 > eps Difference
0
Earnings History > 17 > surprise Percent
0
Earnings History > 18 > period
2021-09-30
Earnings History > 18 > report Date
2021-11-10
Earnings History > 18 > date
2021-09-30
Earnings History > 18 > before After Market
-
Earnings History > 18 > currency
DKK
Earnings History > 18 > eps Actual
13.47
Earnings History > 18 > eps Estimate
13.47
Earnings History > 18 > eps Difference
0
Earnings History > 18 > surprise Percent
0
Earnings History > 19 > period
2021-06-30
Earnings History > 19 > report Date
2021-08-11
Earnings History > 19 > date
2021-06-30
Earnings History > 19 > before After Market
-
Earnings History > 19 > currency
DKK
Earnings History > 19 > eps Actual
4.64
Earnings History > 19 > eps Estimate
4.64
Earnings History > 19 > eps Difference
0
Earnings History > 19 > surprise Percent
0
Earnings History > 20 > period
2021-03-31
Earnings History > 20 > report Date
2021-05-05
Earnings History > 20 > date
2021-03-31
Earnings History > 20 > before After Market
-
Earnings History > 20 > currency
DKK
Earnings History > 20 > eps Actual
16.61
Earnings History > 20 > eps Estimate
16.61
Earnings History > 20 > eps Difference
0
Earnings History > 20 > surprise Percent
0
Earnings History > 21 > period
2020-12-31
Earnings History > 21 > report Date
2021-02-23
Earnings History > 21 > date
2020-12-31
Earnings History > 21 > before After Market
-
Earnings History > 21 > currency
DKK
Earnings History > 21 > eps Actual
8.78
Earnings History > 21 > eps Estimate
9
Earnings History > 21 > eps Difference
-0.22
Earnings History > 21 > surprise Percent
-2.4444
Earnings History > 22 > period
2020-09-30
Earnings History > 22 > report Date
2020-11-04
Earnings History > 22 > date
2020-09-30
Earnings History > 22 > before After Market
-
Earnings History > 22 > currency
DKK
Earnings History > 22 > eps Actual
8.04
Earnings History > 22 > eps Estimate
8.04
Earnings History > 22 > eps Difference
0
Earnings History > 22 > surprise Percent
0
Earnings History > 23 > period
2020-06-30
Earnings History > 23 > report Date
2020-08-13
Earnings History > 23 > date
2020-06-30
Earnings History > 23 > before After Market
-
Earnings History > 23 > currency
DKK
Earnings History > 23 > eps Actual
51.35
Earnings History > 23 > eps Estimate
51.35
Earnings History > 23 > eps Difference
0
Earnings History > 23 > surprise Percent
0
Earnings History > 24 > period
2020-03-31
Earnings History > 24 > report Date
2020-05-06
Earnings History > 24 > date
2020-03-31
Earnings History > 24 > before After Market
-
Earnings History > 24 > currency
DKK
Earnings History > 24 > eps Actual
4.09
Earnings History > 24 > eps Estimate
4.11
Earnings History > 24 > eps Difference
-0.02
Earnings History > 24 > surprise Percent
-0.4866
Earnings History > 25 > period
2019-12-31
Earnings History > 25 > report Date
2020-02-19
Earnings History > 25 > date
2019-12-31
Earnings History > 25 > before After Market
-
Earnings History > 25 > currency
DKK
Earnings History > 25 > eps Actual
23.12
Earnings History > 25 > eps Estimate
22.9
Earnings History > 25 > eps Difference
0.22
Earnings History > 25 > surprise Percent
0.9607
Earnings History > 26 > period
2019-09-30
Earnings History > 26 > report Date
2019-11-06
Earnings History > 26 > date
2019-09-30
Earnings History > 26 > before After Market
-
Earnings History > 26 > currency
DKK
Earnings History > 26 > eps Actual
8.28
Earnings History > 26 > eps Estimate
8.34
Earnings History > 26 > eps Difference
-0.06
Earnings History > 26 > surprise Percent
-0.7194
Earnings History > 27 > period
2019-06-30
Earnings History > 27 > report Date
2019-08-14
Earnings History > 27 > date
2019-06-30
Earnings History > 27 > before After Market
-
Earnings History > 27 > currency
DKK
Earnings History > 27 > eps Actual
1.35
Earnings History > 27 > eps Estimate
1.35
Earnings History > 27 > eps Difference
0
Earnings History > 27 > surprise Percent
0
Earnings History > 28 > period
2019-03-31
Earnings History > 28 > report Date
2019-05-08
Earnings History > 28 > date
2019-03-31
Earnings History > 28 > before After Market
-
Earnings History > 28 > currency
DKK
Earnings History > 28 > eps Actual
1.17
Earnings History > 28 > eps Estimate
1.84
Earnings History > 28 > eps Difference
-0.67
Earnings History > 28 > surprise Percent
-36.413
Earnings History > 29 > period
2018-12-31
Earnings History > 29 > report Date
2019-02-19
Earnings History > 29 > date
2018-12-31
Earnings History > 29 > before After Market
-
Earnings History > 29 > currency
DKK
Earnings History > 29 > eps Actual
13.44
Earnings History > 29 > eps Estimate
8.42
Earnings History > 29 > eps Difference
5.02
Earnings History > 29 > surprise Percent
59.62
Earnings History > 30 > period
2018-09-30
Earnings History > 30 > report Date
2018-11-14
Earnings History > 30 > date
2018-09-30
Earnings History > 30 > before After Market
-
Earnings History > 30 > currency
DKK
Earnings History > 30 > eps Actual
2.89
Earnings History > 30 > eps Estimate
2.63
Earnings History > 30 > eps Difference
0.26
Earnings History > 30 > surprise Percent
9.8859
Earnings History > 31 > period
2018-06-30
Earnings History > 31 > report Date
2018-08-08
Earnings History > 31 > date
2018-06-30
Earnings History > 31 > before After Market
-
Earnings History > 31 > currency
DKK
Earnings History > 31 > eps Actual
4.21
Earnings History > 31 > eps Estimate
2.88
Earnings History > 31 > eps Difference
1.33
Earnings History > 31 > surprise Percent
46.1806
Earnings History > 32 > period
2018-03-31
Earnings History > 32 > report Date
2018-05-08
Earnings History > 32 > date
2018-03-31
Earnings History > 32 > before After Market
-
Earnings History > 32 > currency
DKK
Earnings History > 32 > eps Actual
3.2
Earnings History > 32 > eps Estimate
2.63
Earnings History > 32 > eps Difference
0.57
Earnings History > 32 > surprise Percent
21.673
Earnings History > 33 > period
2017-12-31
Earnings History > 33 > report Date
2018-02-21
Earnings History > 33 > date
2017-12-31
Earnings History > 33 > before After Market
-
Earnings History > 33 > currency
DKK
Earnings History > 33 > eps Actual
12.91
Earnings History > 33 > eps Estimate
0
Earnings History > 33 > eps Difference
12.91
Earnings History > 33 > surprise Percent
-
Earnings History > 34 > period
2017-09-30
Earnings History > 34 > report Date
2017-11-08
Earnings History > 34 > date
2017-09-30
Earnings History > 34 > before After Market
-
Earnings History > 34 > currency
DKK
Earnings History > 34 > eps Actual
-0.09
Earnings History > 34 > eps Estimate
0
Earnings History > 34 > eps Difference
-0.09
Earnings History > 34 > surprise Percent
-
Earnings History > 35 > period
2017-06-30
Earnings History > 35 > report Date
2017-08-09
Earnings History > 35 > date
2017-06-30
Earnings History > 35 > before After Market
-
Earnings History > 35 > currency
DKK
Earnings History > 35 > eps Actual
4.95
Earnings History > 35 > eps Estimate
0
Earnings History > 35 > eps Difference
4.95
Earnings History > 35 > surprise Percent
-
Earnings History > 36 > period
2017-03-31
Earnings History > 36 > report Date
2017-05-11
Earnings History > 36 > date
2017-03-31
Earnings History > 36 > before After Market
-
Earnings History > 36 > currency
DKK
Earnings History > 36 > eps Actual
0.285
Earnings History > 36 > eps Estimate
0
Earnings History > 36 > eps Difference
0.285
Earnings History > 36 > surprise Percent
-
Earnings History > 37 > period
2016-12-31
Earnings History > 37 > report Date
2017-02-22
Earnings History > 37 > date
2016-12-31
Earnings History > 37 > before After Market
-
Earnings History > 37 > currency
DKK
Earnings History > 37 > eps Actual
0
Earnings History > 37 > eps Estimate
0
Earnings History > 37 > eps Difference
0
Earnings History > 37 > surprise Percent
-
Earnings History > 38 > period
2016-09-30
Earnings History > 38 > report Date
2016-11-02
Earnings History > 38 > date
2016-09-30
Earnings History > 38 > before After Market
-
Earnings History > 38 > currency
DKK
Earnings History > 38 > eps Actual
3.05
Earnings History > 38 > eps Estimate
0
Earnings History > 38 > eps Difference
3.05
Earnings History > 38 > surprise Percent
-
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Stock Price
DKK0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2023-06-30)
Health Score
* Institutions hold a combined 0.00% of the total shares of Genmab
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
27.64
Date
2025-09-30
EPS Actual
41.2601
EPS Estimate
31.81
EPS Difference
9.4501
Surprise Percent
29.708%
(Last Updated 2023-06-30)
(Last Updated 2023-06-30)
Revenue
DKK 0
Cost Of Revenue
DKK 0
Gross Profit
DKK 0
Operating Expenses
DKK 0
Operating Income
DKK 0
Interest Expense
DKK 0
Pretax Income
DKK 0
Net Income
DKK 0
Income Tax Expense
DKK 0
EBITDA
DKK 0
Total Other Income Expense Net
DKK 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2023-06-30)
Cash
DKK 0
Short Term Investments
DKK 0
Receivables
DKK 0
Inventories
DKK 0
Total Current Assets
DKK 0
Property Plant Equipment
DKK 0
Total Assets
DKK 0
Payables
DKK 0
Short Term Debt
DKK 0
Long Term Debt
DKK 0
Total Liabilities
DKK 0
Equity
DKK 0
(Last Updated 2023-06-30)
Net Income
DKK 0
Depreciation
DKK 0
Change In Working Capital
DKK 0
Cash From Operations
DKK 0
Capital Expenditures
DKK 0
Cash From Investing
DKK 0
Cash From Financing
DKK 0
Net Change In Cash
DKK 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.